Rabeprazole Sodium
Product Images NDC 50090-3430

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Rabeprazole Sodium (NDC 50090-3430). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500903430)

Label for Rabeprazole Sodium 20 mg delayed release tablets, 90 count, packaged by A-S Medication Solutions. The label includes storage instructions to store at 77 degrees Fahrenheit and protect from moisture. The product NDC is 50090-3430.*

FDA Label Image

Figure 1 (Rabeprazole 01)

FDA Label Image

Figure 2 (Rabeprazole 02)

A line graph showing mean heartburn scores over days for three groups: placebo (n=68), Rabeprazole 10 mg (n=64), and Rabeprazole 20 mg (n=67). The x-axis represents study days from -14 to 28, and the y-axis shows mean scores from 0 (none) to 4 (very severe). The graph illustrates a decrease in heartburn severity after day 0, particularly in Rabeprazole groups compared to placebo.*

FDA Label Image

Figure 3 (Rabeprazole 03)

A line graph depicting mean heartburn scores over a 28-day study period comparing placebo, Rabeprazole 10 mg, and Rabeprazole 20 mg groups. The x-axis represents study days from -14 to 28, and the y-axis represents heartburn scores on a scale from 0 (none) to 4 (very severe). Different line styles correspond to each group.*

FDA Label Image

Figure 4 (Rabeprazole 04)

A line graph comparing mean heartburn scores over a 28-day study period for placebo and Rabeprazole 20 mg groups. The graph shows heartburn severity on the Y-axis from 0 (None) to 4 (Very Severe) and study days on the X-axis from -14 to 28, illustrating changes in symptom scores before and after treatment initiation.*

FDA Label Image

Figure 5 (Rabeprazole 05)

A line graph comparing mean heartburn scores over study days between placebo and Rabeprazole Sodium 20 mg groups. The x-axis represents study days from -14 to 28, and the y-axis shows heartburn severity scores from 0 (none) to 4 (very severe). Two lines plot average scores for placebo (dashed) and Rabeprazole Sodium 20 mg (solid), demonstrating score changes over time.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.